Invention Grant
- Patent Title: Production of differentiated enteroendocrine cells and insulin producing cells
-
Application No.: US15400877Application Date: 2017-01-06
-
Publication No.: US11021687B2Publication Date: 2021-06-01
- Inventor: Jeffrey Michael Karp , Robert Samuel Langer , Xiaolei Yin
- Applicant: Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
- Applicant Address: US MA Cambridge; US MA Boston
- Assignee: Massachusetts Institute of Technology,The Brigham and Women's Hospital, Inc.
- Current Assignee: Massachusetts Institute of Technology,The Brigham and Women's Hospital, Inc.
- Current Assignee Address: US MA Cambridge; US MA Boston
- Agency: Hamilton, Brook, Smith & Reynolds, P.C.
- Main IPC: C12N5/071
- IPC: C12N5/071 ; G01N33/50

Abstract:
A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK/ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.
Public/Granted literature
- US20170349884A1 Production of Differentiated Enteroendocrine Cells and Insulin Producing Cells Public/Granted day:2017-12-07
Information query